PE20191105A1 - Inhibidores de moleculas pequenas de lafamilia de quinasas jak - Google Patents

Inhibidores de moleculas pequenas de lafamilia de quinasas jak

Info

Publication number
PE20191105A1
PE20191105A1 PE2019001252A PE2019001252A PE20191105A1 PE 20191105 A1 PE20191105 A1 PE 20191105A1 PE 2019001252 A PE2019001252 A PE 2019001252A PE 2019001252 A PE2019001252 A PE 2019001252A PE 20191105 A1 PE20191105 A1 PE 20191105A1
Authority
PE
Peru
Prior art keywords
inhibitors
kinas
jak
family
small molecules
Prior art date
Application number
PE2019001252A
Other languages
English (en)
Inventor
Tatiana Koudriakova
Kevin D Kreutter
Kristi Leonard
Michele C Rizzolio
Russell C Smith
Mark S Tichenor
Aihua Wang
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20191105A1 publication Critical patent/PE20191105A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Referido a compuestos de 2-((1r,4r)-4-(imidazo[4,5-d]pirrolo[2,3-b]piridina-1(6H)-il)ciclohexil)acetonitrilo, inhibidores de las quinasas Janus (Jack). Ademas, se refiere a composiciones farmaceuticas, metodos de elaboracion, y su uso en el tratamiento de enfermedades, trastornos y condiciones mediadas por Jack.
PE2019001252A 2016-12-16 2017-12-15 Inhibidores de moleculas pequenas de lafamilia de quinasas jak PE20191105A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662435609P 2016-12-16 2016-12-16
US201762592680P 2017-11-30 2017-11-30
US201762596607P 2017-12-08 2017-12-08
PCT/US2017/066744 WO2018112379A1 (en) 2016-12-16 2017-12-15 Small molecule inhibitors of the jak family of kinases

Publications (1)

Publication Number Publication Date
PE20191105A1 true PE20191105A1 (es) 2019-08-23

Family

ID=61692222

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001252A PE20191105A1 (es) 2016-12-16 2017-12-15 Inhibidores de moleculas pequenas de lafamilia de quinasas jak

Country Status (34)

Country Link
US (5) US10294226B2 (es)
EP (2) EP3555097B1 (es)
JP (2) JP7291077B2 (es)
KR (1) KR102352462B1 (es)
CN (1) CN110088105B (es)
AU (3) AU2017377069B2 (es)
BR (1) BR112019011968A2 (es)
CA (1) CA3046965A1 (es)
CL (1) CL2019001626A1 (es)
CO (1) CO2019006200A2 (es)
CR (1) CR20190282A (es)
DK (1) DK3555097T3 (es)
EC (1) ECSP19042688A (es)
ES (1) ES2922379T3 (es)
HR (1) HRP20220885T1 (es)
HU (1) HUE059274T2 (es)
IL (1) IL267275B (es)
JO (1) JOP20190143B1 (es)
LT (1) LT3555097T (es)
MD (1) MD3555097T2 (es)
MX (2) MX2019007073A (es)
MY (1) MY196260A (es)
NI (1) NI201900060A (es)
PE (1) PE20191105A1 (es)
PH (1) PH12019501254A1 (es)
PL (1) PL3555097T3 (es)
PT (1) PT3555097T (es)
RS (1) RS63500B1 (es)
SA (1) SA519402216B1 (es)
SI (1) SI3555097T1 (es)
TW (1) TWI777997B (es)
UA (1) UA125042C2 (es)
WO (1) WO2018112379A1 (es)
ZA (1) ZA201904615B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10131663B2 (en) 2016-10-24 2018-11-20 Astrazeneca Ab Chemical compounds
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制RORγ及其他用途的嘧啶三環烯酮衍生物
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
JOP20190144A1 (ar) * 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CA3050337A1 (en) 2017-01-30 2018-08-02 Astrazeneca Ab Estrogen receptor modulators
TW202016110A (zh) * 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
US20200338051A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor
MX2021014319A (es) * 2019-06-06 2022-01-26 Highlightll Pharmaceutical Hainan Co Ltd Metodo de sintesis del compuesto de furoimidazopiridina, forma de cristal del compuesto de furoimidazopiridina, y forma de cristal de la sal del mismo.
CN110483514B (zh) * 2019-09-16 2022-06-14 启元生物(杭州)有限公司 一种氰基取代的环肼衍生物及其应用
US20230091250A1 (en) * 2020-02-21 2023-03-23 Zhuhai United Laboratories Co., Ltd. Crystalline form of jak inhibitor and application thereof
CN116925077A (zh) * 2020-09-08 2023-10-24 一又生物(上海)有限公司 吡啶并环类化合物及其制备方法、中间体、组合物和应用
CA3213134A1 (en) 2021-03-11 2022-09-15 Janssen Pharmaceutica Nv Lorpucitinib for use in the treatment of jak mediated disorders
CN113292561A (zh) * 2021-05-22 2021-08-24 中国药科大学 一种二吡咯并吡啶结构的化合物、制备方法和医药用途
CN114432317A (zh) * 2021-05-31 2022-05-06 广州嘉越医药科技有限公司 吡咯并嘧啶类化合物的用途
CN113861194B (zh) * 2021-11-10 2022-07-05 英维沃化工科技(广州)有限公司 一种含吡咯并吡啶双酰胺咪唑类化合物及其制备方法和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
EP1910358A2 (en) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
EP2251341A1 (en) * 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
WO2009152133A1 (en) 2008-06-10 2009-12-17 Abbott Laboratories Novel tricyclic compounds
JP2011066747A (ja) * 2009-09-18 2011-03-31 Panasonic Corp 弾性波フィルタ
AR079234A1 (es) 2009-12-01 2012-01-04 Abbott Lab Derivados heterociclicos condensados nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar afecciones oncologicas, del sistema nervioso y/o del sistema inmune.
NZ599938A (en) 2009-12-01 2014-08-29 Abbvie Inc Novel tricyclic compounds
MX2012008049A (es) 2010-01-12 2012-08-01 Hoffmann La Roche Compuestos heterociclicos triciclicos, composiciones y metodos de uso de los mismos,.
AU2011214254B2 (en) 2010-02-10 2016-06-09 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2924026A1 (en) * 2014-03-28 2015-09-30 Novartis Tiergesundheit AG Aminosulfonylmethylcyclohexanes as JAK inhibitors
EP3303348B1 (en) 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Naphthyridine compounds as jak kinase inhibitors
US20180321235A1 (en) 2015-11-04 2018-11-08 Mayo Foundation For Medical Education And Research Methods and materials for treating autoimmune conditions
US10131663B2 (en) 2016-10-24 2018-11-20 Astrazeneca Ab Chemical compounds
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
US20200077658A1 (en) 2016-12-16 2020-03-12 Basf Se Pesticidal Compounds
LT3555105T (lt) 2016-12-16 2021-01-11 Eli Lilly And Company 7-feniletilamino-4h-pirimido[4,5-d][1,3]oksazin-2-ono junginiai kaip mutantiniai idh1 ir idh2 slopikliai
RU2765752C2 (ru) 2016-12-16 2022-02-02 Сосьете Де Продюи Нестле С.А. Олигосахариды для создания вкусоароматических свойств
DK3555064T5 (da) 2016-12-16 2023-05-01 Pfizer GLP-1 receptoragonister og anvendelser deraf
WO2018112379A1 (en) 2016-12-16 2018-06-21 Janssen Pharmaceutica Nv Small molecule inhibitors of the jak family of kinases
CA3050337A1 (en) 2017-01-30 2018-08-02 Astrazeneca Ab Estrogen receptor modulators
CN110831600B (zh) 2017-04-21 2023-10-17 医肯纳肿瘤学公司 吲哚ahr抑制剂和其用途
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Jak激酶家族之小分子抑制劑
US20200338051A1 (en) 2019-04-24 2020-10-29 Janssen Pharmaceutica Nv Non-clinical liquid formulations of pan-jak inhibitor

Also Published As

Publication number Publication date
UA125042C2 (uk) 2021-12-29
TWI777997B (zh) 2022-09-21
HRP20220885T1 (hr) 2022-12-09
ZA201904615B (en) 2021-05-26
AU2017377069B2 (en) 2020-07-23
JP2023071709A (ja) 2023-05-23
US20190177322A1 (en) 2019-06-13
US11059823B2 (en) 2021-07-13
SA519402216B1 (ar) 2022-10-02
CN110088105A (zh) 2019-08-02
US10487083B2 (en) 2019-11-26
IL267275B (en) 2021-07-29
AU2020257068A1 (en) 2020-11-19
WO2018112379A1 (en) 2018-06-21
CN110088105B (zh) 2022-03-18
CO2019006200A2 (es) 2019-06-28
AU2022204240A1 (en) 2022-07-07
RS63500B1 (sr) 2022-09-30
PT3555097T (pt) 2022-09-22
IL267275A (en) 2019-08-29
ES2922379T3 (es) 2022-09-14
BR112019011968A2 (pt) 2019-11-05
US20180170931A1 (en) 2018-06-21
US10294226B2 (en) 2019-05-21
MY196260A (en) 2023-03-24
JP2020502113A (ja) 2020-01-23
PL3555097T3 (pl) 2022-10-17
EP4086256A1 (en) 2022-11-09
US10364246B2 (en) 2019-07-30
TW201831180A (zh) 2018-09-01
LT3555097T (lt) 2022-08-25
EP3555097B1 (en) 2022-06-15
KR102352462B1 (ko) 2022-01-17
KR20190086779A (ko) 2019-07-23
US20190185474A1 (en) 2019-06-20
US20190177321A1 (en) 2019-06-13
MD3555097T2 (ro) 2022-12-31
DK3555097T3 (da) 2022-07-25
JP7291077B2 (ja) 2023-06-14
SI3555097T1 (sl) 2022-09-30
HUE059274T2 (hu) 2022-11-28
PH12019501254A1 (en) 2020-01-20
NI201900060A (es) 2020-03-16
AU2022204240B2 (en) 2023-10-05
ECSP19042688A (es) 2019-06-30
JOP20190143B1 (ar) 2023-09-17
EP3555097A1 (en) 2019-10-23
MX2019007073A (es) 2019-10-15
AU2017377069A1 (en) 2019-06-20
JOP20190143A1 (ar) 2019-06-13
CL2019001626A1 (es) 2019-10-04
MX2022004474A (es) 2023-08-15
CA3046965A1 (en) 2018-06-21
US20210340143A1 (en) 2021-11-04
CR20190282A (es) 2019-08-21

Similar Documents

Publication Publication Date Title
PE20191105A1 (es) Inhibidores de moleculas pequenas de lafamilia de quinasas jak
PH12019501355A1 (en) Small molecule inhibitors of the jak family of kinases
EA201790995A1 (ru) ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
NI202000100A (es) Inhibidores de moléculas pequeñas de la familia de quinasa jak
EA201891897A1 (ru) 1,5-ДИГИДРО-4H-ПИРАЗОЛО[3,4-d]ПИРИМИДИН-4-ОНЫ И 1,5-ДИГИДРО-4H-ПИРАЗОЛО[4,3-c]ПИРИДИН-4-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1
HRP20182021T1 (hr) Derivati [1,2,4]triazolo[1,5-a]pirimidina kao inhibitori proteazoma protozoe za liječenje parazitskih bolesti poput lišmenijaze
EA201991094A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
EA201991473A1 (ru) Имидазопирролопиридин в качестве ингибиторов киназ семейства jak
EA201991472A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
EA202190047A1 (ru) Низкомолекулярные ингибиторы киназ семейства jak
AR114969A1 (es) Inhibidores de moléculas pequeñas de la familia de quinasas jak